<DOC>
	<DOC>NCT00117624</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy of darbepoetin alfa administered using a front-loading approach with subjects receiving standard weekly dosing in the treatment of anemia in subjects with a non-myeloid malignancy and receiving multicycle chemotherapy.</brief_summary>
	<brief_title>A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Nonmyeloid malignancy At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless of schedule ECOG 02 Cancer and/or chemotherapyassociated anemia Known history of seizure disorder Known primary hematologic disorder, which could cause anemia, other than a nonmyeloid malignancy Unstable or uncontrolled disease/condition, related to or affecting cardiac function Clinically significant inflammatory disease Inadequate renal and/or liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Non-myeloid malignancy</keyword>
	<keyword>Darbepoetin alfa</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>